University of Oklahoma College of Medicine

"As urologists, we should be proactive and creative as we find new ways to attract, retain and train the next generation," writes Michael S. Cookson, MD, MMHC, FACS.

Catch up on exclusive videos you may have missed from the first half of the year.

The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.

"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

In this video, part 4 of a 4-part series, panelists discuss how primary care providers can address patient questions on prostate cancer screening.

In this video, part 2 of a 4-part series, panelists discuss the increasing prevalence of de novo metastatic hormone-sensitive prostate cancer.

In this video, part 1 of a 4-part series, panelists discuss the nuances and challenges of prostate cancer screening.

"“The approval of Gozellix is likely to both streamline and expand access to PSMA-PET imaging, hopefully broadening the distribution and use of gallium 68," says Kelly L. Stratton, MD, FACS.

"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

“I think having the ability to monitor patients with imaging and using things like PSMA-PET is good, but yet we're we sometimes have pitfalls with PSMA-PET too,” says Michael Cookson, MD.

"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of high-risk disease marking key areas of progress," writes Michael S. Cookson, MD, MMHC.

"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.

"The primary aim is looking at the dose-limiting toxicity of this drug combination," says Kelly L. Stratton, MD, FACS.

“This study really bridges the gap between STAMPEDE and PROTEUS and provides the opportunity for patients to get either surgery or radiation therapy,” says Kelly L. Stratton, MD, FACS.

"Unique to this study is that we'll be using Orgovyx," says Kelly L. Stratton, MD, FACS.

Michael S. Cookson, MD, MMHC, FACS, recaps several presentations on prostate cancer from the 2024 American Urological Association Annual Meeting in San Antonio, Texas.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

"I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.

Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

"ctDNA holds a unique position as it offers a molecular means to quantify the extent of residual disease burden," says Adanma Ayanambakkam, MD.

"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.

Kelly L. Stratton, MD, FACS, recaps several presentations on prostate cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.